1. Medical physics aspects of the synchrotron radiation therapies: Microbeam radiation therapy (MRT) and synchrotron stereotactic radiotherapy (SSRT)
- Author
-
Andrew Dipuglia, John Kalef-Ezra, E. Alagoz, Uwe Oelfke, Jean-François Adam, Pauline Fournier, Simon J. Doran, Ciara M. McErlean, Bjarne Stugu, Carlos DeWagter, Pawel Olko, Jeffrey C. Crosbie, Michael L. F Lerch, Mattia Donzelli, Anatoly B. Rosenfeld, Marco Povoli, Angela Kock, Dan Sporea, E.A. Siegbahn, Elke Bräuer-Krisch, Stefan Bartzsch, Marco Petasecca, European Synchrotron Radiation Facility (ESRF), Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Equipe d’accueil rayonnement synchrotron et recherche médicale, Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Department of Physics and Technology [Bergen] (UiB), University of Bergen (UiB), The institute of cancer research [London], School of Applied Sciences, Royal Melbourne Institute of Technology University (RMIT University), William Buckland Radiotherapy Centre, The Alfred Hospital, Ghent University Hospital, Centre for Medical Radiation Physics, University of Wollongong [Australia], CRUK Cancer Imaging Centre, Medical Physics Laboratory, Medical School University of Ioannina, Sintef Minalab, H. Niewodniczanski Institute of Nuclear Physics, Polska Akademia Nauk = Polish Academy of Sciences (PAN), Department of Physics [Oslo], Faculty of Mathematics and Natural Sciences [Oslo], University of Oslo (UiO)-University of Oslo (UiO), Department of Medical Physics, Karolinska Institutet [Stockholm], and National Institute for Laser, Plasma and Radiation Physics (INFLPR)
- Subjects
FORTHCOMING CLINICAL-TRIALS ,Technology Assessment, Biomedical ,Swine ,medicine.medical_treatment ,General Physics and Astronomy ,Synchrotron radiation ,Monte Carlo calculations ,F98 GLIOMA ,Radiation oncology ,030218 nuclear medicine & medical imaging ,law.invention ,Ionizing radiation ,Radiotherapy, High-Energy ,0302 clinical medicine ,SSRT ,law ,Neoplasms ,Medicine and Health Sciences ,DOSE DISTRIBUTIONS ,Physics ,Evidence-Based Medicine ,Brain Neoplasms ,Equipment Design ,General Medicine ,Synchrotron ,3. Good health ,Treatment Outcome ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Synchrotron X-rays ,[PHYS.PHYS.PHYS-MED-PH]Physics [physics]/Physics [physics]/Medical Physics [physics.med-ph] ,Microbeam radiation therapy ,medicine.medical_specialty ,MRT ,Biophysics ,Brain tumor ,X-RAY-BEAMS ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Physics and Astronomy(all) ,Radiosurgery ,MOSFET DOSIMETRY ,Collimated light ,HIGH-SPATIAL-RESOLUTION ,03 medical and health sciences ,Dosimetry ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det] ,Radiometry ,business.industry ,Radiotherapy Planning, Computer-Assisted ,medicine.disease ,equipment and supplies ,GLIOMA-BEARING RATS ,Radiation therapy ,RADIOCHROMIC FILM DOSIMETRY ,IONIZING-RADIATION ,Dose Fractionation, Radiation ,Nuclear medicine ,business ,MONTE-CARLO SIMULATIONS ,Synchrotrons ,Beam divergence ,Biomedical engineering - Abstract
Stereotactic Synchrotron Radiotherapy (SSRT) and Microbeam Radiation Therapy (MRT) are both novel approaches to treat brain tumor and potentially other tumors using synchrotron radiation. Although the techniques differ by their principles, SSRT and MRT share certain common aspects with the possibility of combining their advantages in the future. For MRT, the technique uses highly collimated, quasi-parallel arrays of X-ray microbeams between 50 and 600 keV. Important features of highly brilliant Synchrotron sources are a very small beam divergence and an extremely high dose rate. The minimal beam divergence allows the insertion of so called Multi Slit Collimators (MSC) to produce spatially fractionated beams of typically ~25e75 micron-wide microplanar beams separated by wider (100e400 microns center-to-center(ctc)) spaces with a very sharp penumbra. Peak entrance doses of several hundreds of Gy are extremely well tolerated by normal tissues and at the same time provide a higher therapeutic index for various tumor models in rodents. The hypothesis of a selective radio-vulnerability of the tumor vasculature versus normal blood vessels by MRT was recently more solidified. SSRT (Synchrotron Stereotactic Radiotherapy) is based on a local drug uptake of high-Z elements in tumors followed by stereotactic irradiation with 80 keV photons to enhance the dose deposition only within the tumor. With SSRT already in its clinical trial stage at the ESRF, most medical physics problems are already solved and the implemented solutions are briefly described, while the medical physics aspects in MRT will be discussed in more detail in this paper. © 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Published
- 2015
- Full Text
- View/download PDF